Research programme: obesity therapies - Biocon
Alternative Names: NLC-002Latest Information Update: 10 Apr 2007
At a glance
- Originator Biocon
- Class
- Mechanism of Action Cholecystokinin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 27 Feb 2004 NLC 002 is available for partnering for obesity worldwide (2nd Annual BioPartnering North America Conference (BPN-2004) (http://www.nobexcorp.com)
- 24 Sep 2002 Lead compound of the programme has been identified as NLC 002
- 19 Mar 2002 Preclinical trials in Obesity in USA (PO)